Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib in advanced lung and head and neck cancers with FGFR alterations
NCT01761747Phase 3Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2013
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ponatinib in non-small cell lung cancer, squamous cell carcinoma (NSCLC), head and neck squamous cell carcinoma (HNSCC), sponsored by Dana-Farber Cancer Institute. Started Jan 2013; status: terminated.
02
Drugs
ponatinib
03
Conditions
non-small cell lung cancer, squamous cell carcinoma (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01761747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01761747.